- Home
- COLL vs IGR Comparison
COLL vs IGR Comparison
Compare COLL & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- IGR
- Stock Information
- Founded
- COLL 2002
- IGR 2004
- Country
- COLL United States
- IGR United States
- Employees
- COLL N/A
- IGR N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- IGR Finance Companies
- Sector
- COLL Health Care
- IGR Finance
- Exchange
- COLL Nasdaq
- IGR Nasdaq
- Market Cap
- COLL 910.2M
- IGR 742.1M
- IPO Year
- COLL 2015
- IGR N/A
- Fundamental
- Price
- COLL $30.00
- IGR $5.17
- Analyst Decision
- COLL Strong Buy
- IGR
- Analyst Count
- COLL 5
- IGR 0
- Target Price
- COLL $43.60
- IGR N/A
- AVG Volume (30 Days)
- COLL 444.8K
- IGR 747.7K
- Earning Date
- COLL 05-08-2025
- IGR 01-01-0001
- Dividend Yield
- COLL N/A
- IGR 13.93%
- EPS Growth
- COLL 43.56
- IGR N/A
- EPS
- COLL 1.86
- IGR N/A
- Revenue
- COLL $631,449,000.00
- IGR N/A
- Revenue This Year
- COLL $20.00
- IGR N/A
- Revenue Next Year
- COLL $3.93
- IGR N/A
- P/E Ratio
- COLL $16.09
- IGR N/A
- Revenue Growth
- COLL 11.41
- IGR N/A
- 52 Week Low
- COLL $27.28
- IGR $3.88
- 52 Week High
- COLL $42.29
- IGR $5.70
- Technical
- Relative Strength Index (RSI)
- COLL 51.96
- IGR 47.46
- Support Level
- COLL $29.01
- IGR $5.10
- Resistance Level
- COLL $30.53
- IGR $5.28
- Average True Range (ATR)
- COLL 0.89
- IGR 0.06
- MACD
- COLL 0.04
- IGR -0.00
- Stochastic Oscillator
- COLL 62.91
- IGR 36.11
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is the United States based diversified, closed-end management investment company. Its objective is high current income and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities located mainly in the developed markets of North America, Europe, Australia, and Asia. Its portfolio of investments consists of different sectors such as diversified, retail, industrial, residential, hotels, healthcare, and other sectors.